Sumitomo Mitsui Trust Group Inc. Acquires 15,820 Shares of Hologic, Inc. (NASDAQ:HOLX)

Sumitomo Mitsui Trust Group Inc. boosted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 3.0% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 544,170 shares of the medical equipment provider’s stock after acquiring an additional 15,820 shares during the period. Sumitomo Mitsui Trust Group Inc. owned 0.24% of Hologic worth $39,229,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in HOLX. Prentiss Smith & Co. Inc. boosted its position in shares of Hologic by 0.3% in the 3rd quarter. Prentiss Smith & Co. Inc. now owns 48,696 shares of the medical equipment provider’s stock worth $3,967,000 after purchasing an additional 130 shares during the last quarter. Covestor Ltd boosted its holdings in Hologic by 23.8% during the third quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock worth $56,000 after buying an additional 133 shares during the last quarter. First Horizon Advisors Inc. grew its position in shares of Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 134 shares during the period. Brooklyn Investment Group increased its stake in shares of Hologic by 14.7% in the 4th quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider’s stock valued at $82,000 after acquiring an additional 145 shares during the last quarter. Finally, Empirical Finance LLC raised its position in shares of Hologic by 1.8% in the 3rd quarter. Empirical Finance LLC now owns 8,473 shares of the medical equipment provider’s stock valued at $690,000 after acquiring an additional 147 shares during the period. Institutional investors own 94.73% of the company’s stock.

Hologic Stock Performance

Shares of HOLX opened at $65.24 on Tuesday. The stock has a market capitalization of $14.73 billion, a price-to-earnings ratio of 20.58, a PEG ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a 12 month low of $63.62 and a 12 month high of $84.67. The firm has a fifty day simple moving average of $72.06 and a 200 day simple moving average of $77.67. The company has a current ratio of 3.49, a quick ratio of 3.03 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Research analysts forecast that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

Insider Buying and Selling at Hologic

In other news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. This represents a 47.06 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.88% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on HOLX shares. Evercore ISI decreased their price objective on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating for the company in a report on Thursday, February 6th. StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a report on Thursday, November 14th. Needham & Company LLC downgraded Hologic from a “buy” rating to a “hold” rating and set a $90.00 price objective on the stock. in a research note on Monday, February 3rd. Royal Bank of Canada decreased their target price on Hologic from $88.00 to $85.00 and set a “sector perform” rating for the company in a research note on Thursday, February 6th. Finally, Wolfe Research initiated coverage on Hologic in a research report on Friday, December 13th. They set a “peer perform” rating on the stock. Ten equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Hologic has a consensus rating of “Moderate Buy” and an average price target of $85.77.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.